MCID: BRC084
MIFTS: 46

Brca1 Hereditary Breast and Ovarian Cancer Syndrome malady

Categories: Genetic diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Brca1 Hereditary Breast and Ovarian Cancer Syndrome

About this section

Aliases & Descriptions for Brca1 Hereditary Breast and Ovarian Cancer Syndrome:

Name: Brca1 Hereditary Breast and Ovarian Cancer Syndrome 48
Familial Susceptibility to Breast-Ovarian Cancer 1 48 27
Brca1 Hereditary Breast and Ovarian Cancer 24
Malignant Neoplasm of Breast 68
 
Breast Carcinoma 68
Breast Cancer 24
Brovca1 48

Classifications:



Summaries for Brca1 Hereditary Breast and Ovarian Cancer Syndrome

About this section
NIH Rare Diseases:48 Brca1 hereditary breast and ovarian cancer syndrome (brca1 hboc) is an inherited condition that is characterized by an increased risk for a variety of different cancers. women with this condition have a 57-60% risk of developing breast cancer, a 40-59% risk of developing ovarian cancer and an 83% risk of developing contralateral breast cancer by age 70. men have a 1% lifetime risk of breast cancer and an increased risk for prostate cancer. brca1 hboc may also be associated with an elevated risk for cancers of the cervix, uterus, pancreas, esophagus, stomach, fallopian tube, and primary peritoneum; however, these risks are not well defined. this condition is caused by changes (mutations) in the brca1 gene and is inherited in an autosomal dominant manner. management may include high risk cancer screening, chemoprevention and/or prophylactic surgeries. last updated: 3/10/2015

MalaCards based summary: Brca1 Hereditary Breast and Ovarian Cancer Syndrome, also known as familial susceptibility to breast-ovarian cancer 1, is related to pneumonia and colorectal cancer, and has symptoms including pelvic pain An important gene associated with Brca1 Hereditary Breast and Ovarian Cancer Syndrome is PTEN (Phosphatase And Tensin Homolog), and among its related pathways are Ovarian tumor domain proteases and Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex. Affiliated tissues include breast, cervix and prostate, and related mouse phenotypes are Decreased viability after ionizing radiation and Apoptosis resistance.

Related Diseases for Brca1 Hereditary Breast and Ovarian Cancer Syndrome

About this section

Diseases related to Brca1 Hereditary Breast and Ovarian Cancer Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 156)
idRelated DiseaseScoreTop Affiliating Genes
1pneumonia30.0BRCA1, BRCA2
2colorectal cancer29.2APC, ATM, BRCA1, BRCA2, CHEK2, PTEN
3breast cancer12.7
4familial breast cancer12.4
5bilateral breast cancer12.2
6estrogen-receptor positive breast cancer12.0
7sporadic breast cancer12.0
8estrogen-receptor negative breast cancer12.0
9female breast cancer11.9
10progesterone-receptor positive breast cancer11.9
11triple-receptor negative breast cancer11.9
12progesterone-receptor negative breast cancer11.9
13inflammatory breast carcinoma11.9
14androgen insensitivity, partial, with or without breast cancer11.8
15her2-receptor positive breast cancer11.8
16her2-receptor negative breast cancer11.8
17breast cancer, childhood11.8
18bard1-related susceptibility to breast cancer11.7
19breast cancer susceptibility, xrcc3-related11.7
20brip1-related breast cancer11.7
21chek2-related susceptibility to breast cancer11.7
22rad51-related susceptibility to breast cancer11.7
23gastric cancer risk after h. pylori infection11.4
24breast metaplastic carcinoma11.4
25brca2 hereditary breast and ovarian cancer syndrome11.4
26breast-ovarian cancer, familial, 211.4
27breast-ovarian cancer, familial 411.4
28breast-ovarian cancer, familial, 111.4
29breast-ovarian cancer, familial 311.4
30li-fraumeni syndrome11.4
31pancreatic cancer11.2
32paraneoplastic cerebellar degeneration11.2
33breast fibroadenoma11.2
34granulomatous lobular mastitis11.2
35adenocarcinoma11.1
36paraneoplastic syndromes11.1
37breast sarcoma11.0
38obesity10.9
39comedo carcinoma10.9
40luminal breast carcinoma10.7
41precocious puberty, central, 210.7
42precocious puberty, central, 110.7
43fibrosclerosis of breast10.7
44ocular cancer10.7
45hereditary breast ovarian cancer10.7
46mondor disease10.7
47paraneoplastic neurologic disorders10.7
48endotheliitis10.6
49renal cell carcinoma10.6
50hypoxia10.5

Graphical network of the top 20 diseases related to Brca1 Hereditary Breast and Ovarian Cancer Syndrome:



Diseases related to brca1 hereditary breast and ovarian cancer syndrome

Symptoms & Phenotypes for Brca1 Hereditary Breast and Ovarian Cancer Syndrome

About this section

UMLS symptoms related to Brca1 Hereditary Breast and Ovarian Cancer Syndrome:


pelvic pain

GenomeRNAi Phenotypes related to Brca1 Hereditary Breast and Ovarian Cancer Syndrome according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00232-A-29.9ATM, BRCA1, BRCA2
2GR00093-A-09.9ATM, CHEK2, PTEN
3GR00101-A-49.6BRCA1, BRCA2, BRIP1
4GR00101-A-19.4BRCA1, BRCA2, BRIP1
5GR00151-A-27.4BRCA1, BRCA2, PALB2, ATM, BRCA1, BRCA2
6GR00250-A-37.3ATM, BRCA1, BRCA2, BRIP1, CHEK2, NBN
7GR00250-A-13.6ATM, BRCA1, BRCA2, BRIP1, CHEK2, NBN

MGI Mouse Phenotypes related to Brca1 Hereditary Breast and Ovarian Cancer Syndrome according to GeneCards Suite gene sharing:

41 (show all 13)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053718.6APC, BRCA1, BRCA2, PALB2, PTEN
2MP:00107717.8APC, ATM, BRCA1, BRCA2, PALB2, PTEN
3MP:00053807.8APC, ATM, BRCA1, BRCA2, NBN, PALB2
4MP:00053897.6APC, ATM, BRCA1, BRCA2, BRIP1, NBN
5MP:00053877.6APC, ATM, BRCA1, BRCA2, CHEK2, NBN
6MP:00053787.5APC, ATM, BRCA1, BRCA2, NBN, PALB2
7MP:00053977.2APC, ATM, BRCA1, BRCA2, CHEK2, NBN
8MP:00107687.1APC, ATM, BRCA1, BRCA2, CHEK2, NBN
9MP:00053767.0APC, ATM, BRCA1, BRCA2, BRIP1, CHEK2
10MP:00053796.7APC, ATM, BRCA1, BRCA2, BRIP1, CHEK2
11MP:00020066.5APC, ATM, BRCA1, BRCA2, BRIP1, CHEK2
12MP:00053846.2APC, ATM, BRCA1, BRCA2, BRIP1, CHEK2
13MP:00036316.1APC, ATM, BRCA1, BRCA2, BRIP1, CHEK2

Drugs & Therapeutics for Brca1 Hereditary Breast and Ovarian Cancer Syndrome

About this section

Drugs for Brca1 Hereditary Breast and Ovarian Cancer Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 20)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
CarboplatinapprovedPhase 2, Phase 1205041575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
2
Paclitaxelapproved, vet_approvedPhase 2, Phase 1286433069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nab-paclitaxel
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
3
Doxorubicinapproved, investigationalPhase 2175123214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
4
Cyclophosphamideapproved, investigationalPhase 2293550-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
5
DoxilApproved June 1999Phase 2175131703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
6Antimitotic AgentsPhase 2, Phase 15657
7Antineoplastic Agents, PhytogenicPhase 2, Phase 15602
8Albumin-Bound PaclitaxelPhase 2, Phase 12864
9Alkylating AgentsPhase 24827
10Topoisomerase InhibitorsPhase 25069
11Immunosuppressive AgentsPhase 213086
12Anti-Bacterial AgentsPhase 211226
13Antibiotics, AntitubercularPhase 27180
14Antineoplastic Agents, AlkylatingPhase 24603
15Antirheumatic AgentsPhase 210956
16
VeliparibinvestigationalPhase 199912444-00-911960529
Synonyms:
(2R)-2-(7-carbamoyl-1H-benzimidazol-2-yl)-2-methylpyrrolidinium
2-((2R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide
 
ABT 888
ABT-888
veliparib
17Poly(ADP-ribose) Polymerase InhibitorsPhase 1340
18
Olaparibapproved140763113-22-023725625
Synonyms:
4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one
4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one
4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
763113-22-0
937799-91-2
AKOS005145764
AZD 2281
AZD-2281
AZD2281
 
Acylpiperazine analogue, 47
CHEMBL521686
EC-000.2324
EN002690
FT-0083489
KU-0059436
KU-59436
Olaparib
Olaparib, KU-0059436, AZD2281, KU0059436, AZD2281
S1060_Selleck
olaparib
19
Pancrelipaseapproved97053608-75-6
Synonyms:
1,4-alpha-D- glucan glucanohydrolase
PA
 
Pancreatic alpha-amylase precursor
Pancrelipase (amylase
lipase
protease)
20pancreatin970

Interventional clinical trials:

(show all 25)
idNameStatusNCT IDPhase
1Methods in Education for Breast Cancer GeneticsActive, not recruitingNCT00001806Phase 3
2Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation CarriersNot yet recruitingNCT03162276Phase 3
3Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation CarriersCompletedNCT01367639Phase 2
4Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and/or Ovarian CancerCompletedNCT01333748Phase 2
5Neoadjuvant Carboplatin in Triple Negative Breast CancerRecruitingNCT02978495Phase 2
6A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate CancerRecruitingNCT02203513Phase 2
7Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid CancerCompletedNCT00535119Phase 1
8Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous TherapyActive, not recruitingNCT00892736Phase 1
9Cancer Genetics Hereditary Cancer Panel TestingCompletedNCT02324062
10Risk Education and Assessment for Cancer HeredityCompletedNCT01346761
11Lessons Learned From the Family Gene ToolkitCompletedNCT02154633
12Establishment of Normal Breast Epithelial Cell Lines From Patients at High Risk for Breast CancerCompletedNCT00001496
13Efficacy of Lifestyle Intervention in BRCA1/2 Mutation CarriersRecruitingNCT02516540
14Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier RegistryRecruitingNCT02302742
15Enhancing At-risk Latina Women's Use of Genetic Counseling for Hereditary Breast and Ovarian CancerRecruitingNCT03075540
16Pancreatic Cancer GeneticsRecruitingNCT01102569
17C-PATROL - Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer PopulationRecruitingNCT02503436
18Feasibility of Lifestyle Intervention in BRCA1/2 Mutation CarriersActive, not recruitingNCT02087592
19Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian CancerActive, not recruitingNCT00040222
20Genetic Counseling for Breast Cancer Survivors (GC for BC)Active, not recruitingNCT02451735
21Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian CancerActive, not recruitingNCT01230346
22Identification and Referral of Women at Risk for Hereditary Breast/Ovarian CancerEnrolling by invitationNCT02786147
23Women at Risk of Breast Cancer and OLFM4Not yet recruitingNCT02653105
24Inherited Susceptible Genes Among Epithelial Ovarian CancerNot yet recruitingNCT03015376
25Family Communication of Hereditary Breast and Ovarian Cancer Risk Among African AmericansTerminatedNCT01374685

Search NIH Clinical Center for Brca1 Hereditary Breast and Ovarian Cancer Syndrome

Genetic Tests for Brca1 Hereditary Breast and Ovarian Cancer Syndrome

About this section

Genetic tests related to Brca1 Hereditary Breast and Ovarian Cancer Syndrome:

id Genetic test Affiliating Genes
1 Breast-Ovarian Cancer, Familial 127
2 Brca1 Hereditary Breast and Ovarian Cancer24 BRCA1

Anatomical Context for Brca1 Hereditary Breast and Ovarian Cancer Syndrome

About this section

MalaCards organs/tissues related to Brca1 Hereditary Breast and Ovarian Cancer Syndrome:

36
Breast, Cervix, Prostate, Uterus, Pancreas

Publications for Brca1 Hereditary Breast and Ovarian Cancer Syndrome

About this section

Variations for Brca1 Hereditary Breast and Ovarian Cancer Syndrome

About this section

Clinvar genetic disease variations for Brca1 Hereditary Breast and Ovarian Cancer Syndrome:

5 (show all 57)
id Gene Variation Type Significance SNP ID Assembly Location
1TP53NM_ 000546.5(TP53): c.742C> T (p.Arg248Trp)SNVPathogenic/ Likely pathogenicrs121912651GRCh37Chr 17, 7577539: 7577539
2TP53NM_ 000546.5(TP53): c.733G> T (p.Gly245Cys)SNVPathogenic/ Likely pathogenicrs28934575GRCh37Chr 17, 7577548: 7577548
3TP53NM_ 000546.5(TP53): c.725G> A (p.Cys242Tyr)SNVPathogenic/ Likely pathogenicrs121912655GRCh37Chr 17, 7577556: 7577556
4TP53NM_ 000546.5(TP53): c.734G> A (p.Gly245Asp)SNVPathogenic/ Likely pathogenicrs121912656GRCh37Chr 17, 7577547: 7577547
5TP53NM_ 000546.5(TP53): c.743G> A (p.Arg248Gln)SNVPathogenic/ Likely pathogenicrs11540652GRCh37Chr 17, 7577538: 7577538
6TP53NM_ 000546.5(TP53): c.722C> T (p.Ser241Phe)SNVPathogenic/ Likely pathogenicrs28934573GRCh37Chr 17, 7577559: 7577559
7TP53NM_ 000546.5(TP53): c.733G> A (p.Gly245Ser)SNVPathogenic/ Likely pathogenicrs28934575GRCh37Chr 17, 7577548: 7577548
8TP53NM_ 000546.5(TP53): c.818G> A (p.Arg273His)SNVPathogenic/ Likely pathogenicrs28934576GRCh37Chr 17, 7577120: 7577120
9TP53NM_ 000546.5(TP53): c.451C> A (p.Pro151Thr)SNVPathogenic/ Likely pathogenicrs28934874GRCh37Chr 17, 7578479: 7578479
10TP53NM_ 000546.5(TP53): c.451C> T (p.Pro151Ser)SNVPathogenic/ Likely pathogenicrs28934874GRCh37Chr 17, 7578479: 7578479
11HRASNM_ 005343.3(HRAS): c.34G> A (p.Gly12Ser)SNVPathogenic/ Likely pathogenicrs104894229GRCh37Chr 11, 534289: 534289
12HRASNM_ 005343.3(HRAS): c.35G> C (p.Gly12Ala)SNVPathogenic/ Likely pathogenicrs104894230GRCh37Chr 11, 534288: 534288
13HRASNM_ 005343.3(HRAS): c.37G> T (p.Gly13Cys)SNVPathogenic/ Likely pathogenicrs104894228GRCh37Chr 11, 534286: 534286
14HRASNM_ 005343.3(HRAS): c.35G> A (p.Gly12Asp)SNVPathogenic/ Likely pathogenicrs104894230GRCh37Chr 11, 534288: 534288
15HRASNM_ 005343.3(HRAS): c.34G> T (p.Gly12Cys)SNVPathogenic/ Likely pathogenicrs104894229GRCh37Chr 11, 534289: 534289
16TP53NM_ 000546.5(TP53): c.488A> G (p.Tyr163Cys)SNVPathogenic/ Likely pathogenicrs148924904GRCh37Chr 17, 7578442: 7578442
17TP53NM_ 000546.5(TP53): c.535C> T (p.His179Tyr)SNVPathogenic/ Likely pathogenicrs587780070GRCh37Chr 17, 7578395: 7578395
18TP53NM_ 000546.5(TP53): c.659A> G (p.Tyr220Cys)SNVPathogenic/ Likely pathogenicrs121912666GRCh37Chr 17, 7578190: 7578190
19TP53NM_ 000546.5(TP53): c.701A> G (p.Tyr234Cys)SNVPathogenic/ Likely pathogenicrs587780073GRCh37Chr 17, 7577580: 7577580
20TP53NM_ 000546.5(TP53): c.638G> A (p.Arg213Gln)SNVPathogenic/ Likely pathogenicrs587778720GRCh38Chr 17, 7674893: 7674893
21PIK3CANM_ 006218.3(PIK3CA): c.3140A> G (p.His1047Arg)SNVPathogenic/ Likely pathogenicrs121913279GRCh37Chr 3, 178952085: 178952085
22PIK3CANM_ 006218.3(PIK3CA): c.3140A> T (p.His1047Leu)SNVPathogenic/ Likely pathogenicrs121913279GRCh37Chr 3, 178952085: 178952085
23PIK3CANM_ 006218.3(PIK3CA): c.1633G> A (p.Glu545Lys)SNVPathogenic/ Likely pathogenicrs104886003GRCh37Chr 3, 178936091: 178936091
24PIK3CANM_ 006218.3(PIK3CA): c.1634A> G (p.Glu545Gly)SNVPathogenic/ Likely pathogenicrs121913274GRCh37Chr 3, 178936092: 178936092
25AKT1NM_ 005163.2(AKT1): c.49G> A (p.Glu17Lys)SNVPathogenic/ Likely pathogenicrs121434592GRCh37Chr 14, 105246551: 105246551
26TP53NM_ 000546.5(TP53): c.422G> A (p.Cys141Tyr)SNVPathogenic/ Likely pathogenicrs587781288GRCh37Chr 17, 7578508: 7578508
27TP53NM_ 000546.5(TP53): c.844C> G (p.Arg282Gly)SNVPathogenic/ Likely pathogenicrs28934574GRCh37Chr 17, 7577094: 7577094
28TP53NM_ 000546.5(TP53): c.842A> G (p.Asp281Gly)SNVPathogenic/ Likely pathogenicrs587781525GRCh37Chr 17, 7577096: 7577096
29IDH1NM_ 001282386.1(IDH1): c.395G> A (p.Arg132His)SNVPathogenic/ Likely pathogenicrs121913500GRCh38Chr 2, 208248388: 208248388
30PIK3CANM_ 006218.3(PIK3CA): c.1634A> C (p.Glu545Ala)SNV, HaplotypePathogenic/ Likely pathogenicrs121913274GRCh37Chr 3, 178936092: 178936092
31HRASNM_ 005343.3(HRAS): c.38G> T (p.Gly13Val)SNVPathogenic/ Likely pathogenicrs104894226GRCh38Chr 11, 534285: 534285
32TP53NM_ 000546.5(TP53): c.842A> T (p.Asp281Val)SNVPathogenic/ Likely pathogenicrs587781525GRCh38Chr 17, 7673778: 7673778
33TP53NM_ 000546.5(TP53): c.856G> A (p.Glu286Lys)SNVPathogenic/ Likely pathogenicrs786201059GRCh37Chr 17, 7577082: 7577082
34TP53NM_ 000546.5(TP53): c.824G> A (p.Cys275Tyr)SNVPathogenic/ Likely pathogenicrs863224451GRCh38Chr 17, 7673796: 7673796
35TP53NM_ 000546.5(TP53): c.584T> C (p.Ile195Thr)SNVPathogenic/ Likely pathogenicrs760043106GRCh38Chr 17, 7674947: 7674947
36PIK3CANM_ 006218.3(PIK3CA): c.1635G> T (p.Glu545Asp)SNVPathogenic/ Likely pathogenicrs121913275GRCh37Chr 3, 178936093: 178936093
37TP53NM_ 000546.5(TP53): c.833C> T (p.Pro278Leu)SNVPathogenic/ Likely pathogenicrs876659802GRCh37Chr 17, 7577105: 7577105
38SMAD4NM_ 005359.5(SMAD4): c.1081C> G (p.Arg361Gly)SNVPathogenic/ Likely pathogenicrs80338963GRCh37Chr 18, 48591918: 48591918
39SMAD4NM_ 005359.5(SMAD4): c.1082G> A (p.Arg361His)SNVPathogenic/ Likely pathogenicrs377767347GRCh37Chr 18, 48591919: 48591919
40PIK3CANM_ 006218.3(PIK3CA): c.1624G> A (p.Glu542Lys)SNVPathogenic/ Likely pathogenicrs121913273GRCh37Chr 3, 178936082: 178936082
41HRASNM_ 005343.3(HRAS): c.37G> C (p.Gly13Arg)SNVPathogenic/ Likely pathogenicrs104894228GRCh37Chr 11, 534286: 534286
42IDH1NM_ 005896.3(IDH1): c.395G> T (p.Arg132Leu)SNVPathogenic/ Likely pathogenicrs121913500GRCh37Chr 2, 209113112: 209113112
43IDH1NM_ 001282387.1(IDH1): c.394C> T (p.Arg132Cys)SNVPathogenic/ Likely pathogenicrs121913499GRCh37Chr 2, 209113113: 209113113
44IDH1NM_ 001282387.1(IDH1): c.394C> G (p.Arg132Gly)SNVPathogenic/ Likely pathogenicrs121913499GRCh37Chr 2, 209113113: 209113113
45IDH1NM_ 001282387.1(IDH1): c.394C> A (p.Arg132Ser)SNVPathogenic/ Likely pathogenicrs121913499GRCh37Chr 2, 209113113: 209113113
46PIK3CANM_ 006218.3(PIK3CA): c.1633G> C (p.Glu545Gln)SNVPathogenic/ Likely pathogenicrs104886003GRCh37Chr 3, 178936091: 178936091
47ERBB2NM_ 004448.3(ERBB2): c.2305G> C (p.Asp769His)SNVPathogenic/ Likely pathogenicrs121913468GRCh38Chr 17, 39724008: 39724008
48ERBB2NM_ 001005862.2(ERBB2): c.2215G> T (p.Asp739Tyr)SNVPathogenic/ Likely pathogenicrs121913468GRCh37Chr 17, 37880261: 37880261
49ERBB2NM_ 004448.3(ERBB2): c.2524G> A (p.Val842Ile)SNVPathogenic/ Likely pathogenicrs1057519738GRCh37Chr 17, 37881332: 37881332
50TP53NM_ 000546.5(TP53): c.713G> T (p.Cys238Phe)SNVPathogenic/ Likely pathogenicrs730882005GRCh37Chr 17, 7577568: 7577568
51TP53NM_ 000546.5(TP53): c.523C> G (p.Arg175Gly)SNVPathogenic/ Likely pathogenicrs138729528GRCh37Chr 17, 7578407: 7578407
52PIK3CANM_ 006218.3(PIK3CA): c.3139C> T (p.His1047Tyr)SNVPathogenic/ Likely pathogenicrs121913281GRCh37Chr 3, 178952084: 178952084
53BRAFNM_ 004333.4(BRAF): c.1391G> T (p.Gly464Val)SNVPathogenic/ Likely pathogenicrs121913348GRCh37Chr 7, 140481417: 140481417
54PTENNM_ 000314.6(PTEN): c.697C> T (p.Arg233Ter)SNVPathogenicrs121909219GRCh37Chr 10, 89717672: 89717672
55PTENNM_ 000314.6(PTEN): c.389G> A (p.Arg130Gln)SNVPathogenic/ Likely pathogenicrs121909229GRCh37Chr 10, 89692905: 89692905
56SMAD4NM_ 005359.5(SMAD4): c.1081C> T (p.Arg361Cys)SNVPathogenic/ Likely pathogenicrs80338963GRCh37Chr 18, 48591918: 48591918
57PTENNM_ 000314.6(PTEN): c.800delA (p.Lys267Argfs)deletionPathogenicrs121913289GRCh37Chr 10, 89717775: 89717775

Expression for genes affiliated with Brca1 Hereditary Breast and Ovarian Cancer Syndrome

About this section
Search GEO for disease gene expression data for Brca1 Hereditary Breast and Ovarian Cancer Syndrome.

Pathways for genes affiliated with Brca1 Hereditary Breast and Ovarian Cancer Syndrome

About this section

Pathways related to Brca1 Hereditary Breast and Ovarian Cancer Syndrome according to GeneCards Suite gene sharing:

(show all 38)
idSuper pathwaysScoreTop Affiliating Genes
19.8APC, PTEN
29.7ATM, PTEN
39.7ATM, BRCA1
49.7ATM, BRCA1
59.6BRCA1, NBN
6
Show member pathways
9.5ATM, NBN
7
Show member pathways
9.5ATM, CHEK2
89.5ATM, CHEK2
99.5BRCA2, CHEK2
109.4APC, ATM, PTEN
11
Show member pathways
9.2ATM, CHEK2, PTEN
129.2ATM, BRCA1, NBN
139.2APC, ATM, CHEK2
14
Show member pathways
9.2APC, ATM, CHEK2
159.0APC, ATM, BRCA1, PTEN
169.0ATM, CHEK2, NBN
178.9ATM, BRCA1, CHEK2, PTEN
188.9ATM, BRCA1, CHEK2, PTEN
19
Show member pathways
8.9ATM, BRCA1, CHEK2, PTEN
20
Show member pathways
8.7ATM, BRCA1, BRCA2, NBN
21
Show member pathways
8.7ATM, BRCA1, CHEK2, NBN
228.7ATM, BRCA1, CHEK2, NBN
23
Show member pathways
8.7ATM, BRCA1, CHEK2, NBN
24
Show member pathways
8.6APC, ATM, BRCA1, BRCA2, PTEN
258.4ATM, BRCA1, BRCA2, CHEK2, PTEN
26
Show member pathways
8.4ATM, BRCA1, CHEK2, NBN, PTEN
27
Show member pathways
8.2BRCA1, BRCA2, BRIP1, PALB2
28
Show member pathways
8.2ATM, BRCA1, BRCA2, CHEK2, NBN
29
Show member pathways
8.2ATM, BRCA1, BRCA2, CHEK2, NBN
30
Show member pathways
7.9ATM, BRCA1, BRIP1, CHEK2, NBN
31
Show member pathways
7.5ATM, BRCA1, BRIP1, CHEK2, NBN, PTEN
32
Show member pathways
7.5ATM, BRCA1, BRIP1, CHEK2, NBN, PTEN
337.4ATM, BRCA1, BRCA2, BRIP1, CHEK2, NBN
34
Show member pathways
7.4ATM, BRCA1, BRCA2, BRIP1, CHEK2, NBN
35
Show member pathways
7.4ATM, BRCA1, BRCA2, BRIP1, CHEK2, NBN
36
Show member pathways
7.3ATM, BRCA1, BRCA2, BRIP1, NBN, PALB2
37
Show member pathways
7.3ATM, BRCA1, BRCA2, BRIP1, NBN, PALB2
38
Show member pathways
6.8ATM, BRCA1, BRCA2, BRIP1, CHEK2, NBN

GO Terms for genes affiliated with Brca1 Hereditary Breast and Ovarian Cancer Syndrome

About this section

Cellular components related to Brca1 Hereditary Breast and Ovarian Cancer Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1lateral elementGO:000080010.5BRCA1, BRCA2
2nuclear chromosome, telomeric regionGO:00007849.9ATM, BRCA2, NBN
3chromosome, telomeric regionGO:00007819.8ATM, CHEK2, NBN
4PML bodyGO:00166059.1CHEK2, NBN, PTEN
5nucleoplasmGO:00056546.9APC, ATM, BRCA1, BRCA2, BRIP1, CHEK2
6nucleusGO:00056346.6APC, ATM, BRCA1, BRCA2, BRIP1, CHEK2

Biological processes related to Brca1 Hereditary Breast and Ovarian Cancer Syndrome according to GeneCards Suite gene sharing:

(show all 31)
idNameGO IDScoreTop Affiliating Genes
1chordate embryonic developmentGO:004300910.4BRCA1, BRCA2
2mitotic spindle assembly checkpointGO:000709410.4APC, ATM
3female gonad developmentGO:000858510.3ATM, BRCA2
4cellular response to gamma radiationGO:007148010.3ATM, CHEK2
5DNA damage induced protein phosphorylationGO:000697510.3ATM, CHEK2
6negative regulation of telomere cappingGO:190435410.2ATM, NBN
7intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorGO:004277110.2BRCA2, CHEK2
8inner cell mass cell proliferationGO:000183310.1BRCA2, PALB2
9protein deubiquitinationGO:001657910.1APC, BRCA1, PTEN
10replicative senescenceGO:009039910.1ATM, CHEK2
11response to gamma radiationGO:001033210.0BRCA2, CHEK2
12DNA double-strand break processingGO:00007299.9ATM, BRCA1, NBN
13cell cycle arrestGO:00070509.9APC, ATM, NBN
14double-strand break repair via nonhomologous end joiningGO:00063039.9ATM, BRCA1, NBN
15DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:00069789.9BRCA1, BRCA2, CHEK2
16DNA duplex unwindingGO:00325089.9BRIP1, NBN
17somitogenesisGO:00017569.8ATM, PALB2
18regulation of apoptotic processGO:00429819.8ATM, BRCA1, CHEK2
19DNA recombinationGO:00063109.8BRCA1, BRCA2, PALB2
20apoptotic processGO:00069159.6ATM, BRCA1, CHEK2, PTEN
21intrinsic apoptotic signaling pathway in response to DNA damageGO:00086309.4ATM, BRCA1, BRCA2, CHEK2
22DNA damage checkpointGO:00000779.3BRIP1, CHEK2, NBN
23DNA replicationGO:00062609.1ATM, BRCA1, BRIP1, NBN
24cell cycleGO:00070499.0ATM, BRCA1, BRCA2, CHEK2, NBN
25double-strand break repair via homologous recombinationGO:00007248.8ATM, BRCA1, BRCA2, NBN, PALB2
26double-strand break repairGO:00063028.5BRCA1, BRCA2, BRIP1, CHEK2, NBN
27regulation of signal transduction by p53 class mediatorGO:19017968.4ATM, BRCA1, BRIP1, CHEK2, NBN
28DNA synthesis involved in DNA repairGO:00007318.0ATM, BRCA1, BRCA2, BRIP1, NBN, PALB2
29DNA repairGO:00062817.5ATM, BRCA1, BRCA2, BRIP1, CHEK2, NBN
30strand displacementGO:00007327.3ATM, BRCA1, BRCA2, BRIP1, NBN, PALB2
31cellular response to DNA damage stimulusGO:00069747.1APC, ATM, BRCA1, BRCA2, BRIP1, CHEK2

Molecular functions related to Brca1 Hereditary Breast and Ovarian Cancer Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1ATP-dependent DNA helicase activityGO:00040039.7BRIP1, NBN
2ubiquitin protein ligase bindingGO:00316259.2APC, BRCA1, CHEK2

Sources for Brca1 Hereditary Breast and Ovarian Cancer Syndrome

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet